Continucare Stock Hits New 52-Week High (CNU)

NEW YORK ( TheStreet) -- Continucare (NYSE: CNU) hit a new 52-week high Tuesday as it is currently trading at $6.45, above its previous 52-week high of $6.43 with 1.9 million shares traded as of 3:55 p.m. ET. Average volume has been 558,500 shares over the past 30 days.

Continucare has a market cap of $388.1 million and is part of the health care sector and health services industry. Shares are up 35.7% year to date as of the close of trading on Monday.

Continucare Corporation provides primary care physician services on an outpatient basis in Florida, the United States. It offers medical services to patients through physicians, nurse practitioners, and physicians' assistants. The company has a P/E ratio of 16.8, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7.
  • Practice your CNU trading strategies and win cash in our stock game.

TheStreet Ratings rates Continucare as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Continucare Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Tuesday Turnaround in Politics: Is a Trade War on the Horizon?

Tuesday Turnaround in Politics: Is a Trade War on the Horizon?

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target